Clinical trials: gemcitabine hydrochloride
Biliary Tract Cancer
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
A Real-World Study of Durvalumab combined with Surufatinib as maintenance therapy in patients with advanced biliary tract cancer whose disease did not progress after completion of first-line Durvalumab combined with…
- Trial name
- NCT06255262
- Testing
- Surufatinib, Durvalumab
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Osteosarcoma Recurrent, Osteosarcoma Metastatic
Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment
- Trial name
- NCT04651179
- Testing
- observation
- Where
- 8 sites in Italy
- Volunteers
- 33 people
- Sponsor
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube…
- Trial name
- NCT07769502
- Testing
- Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in United States, Israel and 2 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Pancreatic Cancer
Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if gemcitabine is more effective with or without capecitabine in treating pancreatic…
- Trial name
- NCT00030732
- Testing
- Gemcitabine + Capecitabine, Gemcitabine alone
- Where
- 18 sites in Austria, Israel and 2 more
- Volunteers
- 319 people
- Sponsor
- Swiss Cancer Institute
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it…
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05685602
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
FIL_Dara-GDP is a phase II, open label, multicenter clinical trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL).
- Trial name
- NCT04251065
- Testing
- Daratumumab
- Where
- 7 sites in Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Non-small Cell Lung Cancer
Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to investigate the efficacy of BAI Plus 3DCRT in local advanced NSCLC.
- Trial name
- DO201001 (NCT01201044)
- Testing
- Gemcitabine, Nedaplatin, iV, 3DCRT, Gemcitabine，Nedaplatin, BAI
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Third Military Medical University
UTUC, UC (Urothelial Cancer)
A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma
This is a single-center, open-label, non-randomized controlled trial comparing the efficacy and safety of neoadjuvant chemotherapy (NAC) followed by radical surgery versus upfront radical surgery alone in patients with high-risk…
- Trial name
- NCT07155044
- Testing
- NAC
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changhai Hospital
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma
- Trial name
- NCT04458909
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- 325 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms (Locally Advanced Non-metastatic)
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread beyond the pancreas.
- Trial name
- SCALOP-2 (NCT02024009)
- Testing
- nab-paclitaxel, 60Gy in 30#, 50.4Gy in 28#
- Where
- 23 sites in United Kingdom
- Volunteers
- 159 people
- Sponsor
- University of Oxford
Pancreatic Cancer, Thromboembolism
The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
This is a prospective, randomized, multicenter, open-label, blinded-endpoint Phase III clinical trial to investigate the impact of thromboprophylaxis using innohep, beyond anticoagulation in the improvement of the clinical…
- Trial name
- imPaCT-PRO (NCT05178628)
- Testing
- Innohep, Chemotherapy: Gemcitabine + Nab-Paclitaxel
- Where
- 2 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Michalis Karamouzis
Cholangiocarcinoma Non-resectable, Non-metastatic
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
We hypothesized that intra-arterial gemcitabine/oxaliplatin administered as second-line treatment could strongly improve objective response rate at 4 months after inclusion in patient with non-metastatic unresectable…
- Trial name
- GEMOXIA-02 (NCT03364530)
- Testing
- Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy
- Where
- 7 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Montpellier
Pancreatic Cancer
Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416507
- Testing
- fluorouracil, gemcitabine hydrochloride, liposomal cisplatin
- Volunteers
- 190 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Advanced Pancreatic Ductal Adenocarcinoma
ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.
This study is testing whether adding three drugs, All-Trans Retinoic Acid (ATRA), SDK002 (also called Arsenic Trioxide or ATO), and tislelizumab, to standard chemotherapy is safe for people with advanced pancreatic cancer.
- Trial name
- ATARI-PDAC (NCT07348107)
- Testing
- ATRA, Arsenic Trioxide (ATO), Gemcitabine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Daniel Breadner
Biliary Tract Malignancies
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
Evaluating the efficacy and safety of adebrelimab in combination with apatinib, gemcitabine and cisplatin in the neoadjuvant treatment of patients with biliary tract malignancies.
- Trial name
- NCT06181032
- Testing
- Adebrelimab, Apatinib, Gemcitabine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Pancreatic Cancer
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different indications.
- Trial name
- NCT02395016
- Testing
- nimotuzumab, Gemcitabine
- Where
- 25 sites in China
- Volunteers
- 90 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Metastatic Pancreatic Cancer
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
The investigators are to evaluate the efficacy and safety of FOLFOX or FOLFIRI.3 combination chemotherapy as second-line salvage chemotherapy in patients with advanced pancreatic carcinoma.
- Trial name
- NCT00786006
- Testing
- FOLFIRI.3, FOLFOX
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Asan Medical Center
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreatic Cancer
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Phase III Metastatic Pancreatic Cancer
- Trial name
- NCT00844649
- Testing
- Albumin-bound paclitaxel (ABI-007), Gemcitabine
- Where
- 193 sites in United States, Australia and 9 more
- Volunteers
- 861 people
- Sponsor
- Celgene
Bladder Cancer
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
This study will compare the effects, good and/or bad, of chemotherapy (Gemcitabine and Cisplatin) with or without the addition of the chemotherapy drug Cetuximab to find out which treatment is better.
- Trial name
- NCT00645593
- Testing
- Gemcitabine,, Cisplatin, Cetuximab
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.